NPCE News and Press, Neuropace Inc. From 01/31/24

2024-01-31 19:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-21 16:50:33 ET More on Pacific Biosciences of California, AVITA Medical, etc. AVITA Medical Positioned For Stellar 2024 With Skin Repair Innovation Momentum Pacific Biosciences' Revio And Onso Lead Looks Priced In For Now Reassessing Pacific Biosciences: Deep...

2024-01-08 11:48:30 ET More on NeuroPace NeuroPace: Making Strides In The Epilepsy Market NeuroPace, Inc. (NPCE) Q3 2023 Earnings Call Transcript NeuroPace, Inc. 2023 Q3 - Results - Earnings Call Presentation NeuroPace GAAP EPS of -$0.28 beats by $0.13, reven...

Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and between $64.9 million and $65.4 million for full year 2023 Company begins 2024 with cash balance of $66.5 million Announces completion of patient implant milestone in the NAUTILU...

NAUTILUS is the first and only pivotal clinical study to evaluate neuromodulation therapy for treating drug refractory idiopathic generalized epilepsy Neuromodulation therapy is not currently indicated for patients with drug refractory generalized epilepsy If successful, NeuroPa...

2023-12-20 02:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

MOUNTAIN VIEW, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 42 nd Annual J.P. Morgan Healthcare...

2023-12-07 14:27:37 ET Summary Today, we take a look at NeuroPace, Inc., a medical device company that has developed a brain-responsive neuromodulation system for treating epilepsy. The stock has doubled since this summer, posted better than Q3 results in November, and has done a ...

First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial In strategic data collaboration, clinical-stage biotechnology company to pay NeuroPace up to...

MOUNTAIN VIEW, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will have a substantial presence at the 77th American Epilepsy Soci...